Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis

Angelo Coppola; Krisstopher Richard Flores; Francesca De Filippis

doi:10.1016/j.rmcr.2020.101050

Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis

Respir Med Case Rep. 2020 Apr 4:30:101050. doi: 10.1016/j.rmcr.2020.101050. eCollection 2020.

Authors

Angelo Coppola¹, Krisstopher Richard Flores¹, Francesca De Filippis¹

Affiliation

¹ UOC Malattie dell'Apparato Respiratorio, Ospedale "Regina Apostolorum", Albano Laziale, RM, Italy.

Abstract

A 63 years - old woman affected by severe eosinophilic asthma associated with EGPA presented refractory respiratory symptoms, resistant to high dose oral corticosteroid treatment. A significant hyper-eosinophilia was present at the blood test, and the ACT score was steadily low, despite the maximal dose of inhalation therapy. The CT chest scan showed a persistent diffuse bronchial wall thickening, pulmonary infiltration and paranasal sinusitis. We report here the rapid onset of effect of benralizumab 30 mg in a monthly subcutaneous injection in reducing patient's symptom, inducing regression of CT scan abnormalities, determining a steroid sparing effect and improving lung function tests after 3 months of therapy. A fast and stable reduction of peripheral eosinophilia associated with an increase in ACT score were also documented after the first dose of benralizumab.

Keywords: Anti IL-5Ra; Benralizumab; Churg; EGPA; Eosinophils; Strauss syndrome.

Publication types

Case Reports